Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin-6

Prostate

Volumn 56, Issue 2, 2003, Pages 106-109

  Akakura, Koichiro ^a,b   Suzuki, Hiroyoshi ^a   Ueda, Takeshi ^a   Komiya, Akira ^a   Ichikawa, Tomohiko ^a   Igarashi, Tatsuo ^a   Ito, Haruo ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TOKYO KOSEI NENKIN HOSPITAL   (Japan)

Author keywords

Androgen ablation; Glucocorticoid; Interleukin 6; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROSTENEDIONE; DEXAMETHASONE; INTERLEUKIN 6; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; GLUCOCORTICOID; TESTOSTERONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG INHIBITION; HORMONE INHIBITION; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; ADENOCARCINOMA; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; PROSTATE TUMOR; TREATMENT OUTCOME;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT OUTCOME;

EID: 0042809897     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10231     Document Type: Article

References (18)

1. Scher HI, Kelly WK. Flutamide withdrawal syndrome: Its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-1572.
2. Akakura K, Akimoto S, Furuya Y, Ito H. Incidence and characteristics of antiandrogen withdrawal syndrome in prostate cancer after treatment with chlormadinone acetate. Eur Urol 1998;33:567-571.
3. Scher HI, Steineck G, Kelly WK. Hormone-refractory (D3) prostate cancer: Refining the concept. Urology 1995;46:142-148.
4. Stolie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100.
5. Nishiyama T, Terunuma M. Hormone/antihormone withdrawal and dexamethasone for hormone-refractory prostate cancer. Int J Urol 1998;5:44-47.
6. Nishimura K, Nonomura N, Yasunaga Y, Takaha N, Inoue H, Sugao H, Yamaguchi S, Ukimura O, Miki T, Okuyama A. Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer 2000;89:2570-2576.
7. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, Tokizane T, Fukui T, Ono Y, Inoue H, Shin M, Tsujimoto Y, Takayama H, Aozasa K, Okuyama A. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001;93:1739-1746.
8. Hobisch A, Rogatsch H, Hittmair A, Fuchs D, Bartsch G Jr., Klocker H, Bartsch G, Culig Z. Immunohistochemical localization of interleukin-6 and its receptor in benign, pre-malignant and malignant prostate tissue. J Pathol 2000;191:239-244.
9. Ray A, Zhang D-G, Siegel MD, Ray P. Regulation of Interleukin-6 gene expression by steroids. In: Mackiewicz A, Koj A, Sehgal PB, editors. Interleukin-6-type cytokines. New York: Ann NY Acad Sci; 1995. pp 79-88.
10. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res 1997;57:141-146.
11. Chung TD, Yu JJ, Spiotto MT, Bartkowski M, Simons JW. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate 1999;38:199-207.
12. Lou W, Ni Z, Dyer K, Tweardy DJ, Gao AC. Interleukin-6 induces prostate cancer cell growth accompanied by activation of STAT3 signaling pathway. Prostate 2000;42:239-242.
13. Hobisch A, Eder IE, Putz T, Horninger W, Bartsch G, Klocker H, Culig Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res 1998;58:4640-4645.
14. Chen T, Wang LH, Farrar WL. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 2000;60:2132-2135.
15. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem 2002;277:7076-7085.
16. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-133.
17. Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M. Serum interleukin-6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 2000;6:2702-2706.
18. Takeda H, Akakura K, Masai M, Akimoto S, Yatani R, Shimazaki J. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma. Cancer 1996;77:934-940.